Last Updated on November 11, 2022 by GlobeNewsWire
Negma Group has converted 130 convertible bonds in Oxurion resulting in a EUR 325,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BELGIUM, Boston, MA, US – November 11, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 16,250,000 new ordinary shares on November 7, 2022, for a total amount of EUR 325,000, as the result of the conversion of 130 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 109,075,765 outstanding ordinary shares carrying voting rights (compared to 92,825,765 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
Share capital (EUR)72,981,161.32 Total number of securities with voting rights (all ordinary shares)109,075,765 Total number of ordinary shares (= denominator)109,075,765 Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued: 719,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 719,500 securities carrying voting rights (all ordinary shares); 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);1,007,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 1,007,250 securities carrying voting rights (all ordinary shares);550,000 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares);725,749 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 725,749 securities carrying voting rights (all ordinary shares);810 convertible bonds issued on September 5, 2022, and 21 October 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021, and the addendum thereto dated September 2, 2022; and100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at http://www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 firstname.lastname@example.org
Michaël DillenChief Business OfficerTel: +32 16 75 13 email@example.com
US Conway CommunicationsBeth Kurthbkurth@conwaycommsir.com
ICR WestwickeChristopher BrinzeyTel: +1 617 835 firstname.lastname@example.org